Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of medical economics"
DOI: 10.1080/13696998.2021.1877148
Abstract: AIMS To assess healthcare costs and hospitalization rates associated with rifaximin therapy versus lactulose alone among patients at risk for hepatic encephalopathy (HE). METHODS AND MATERIALS IBM Marketscan® Commercial and Optum's de-identified Clinformatics® Data Mart… read more here.
Keywords: associated rifaximin; healthcare costs; versus lactulose; lactulose alone ... See more keywords